Taken together, our study demonstrated that β-lap, a novel NQO1 bioactivatable drug, selectively kills HCC cells expressing NQO1 through inducing ROS and PAR formation, NAD+ and ATP depletion and lethal DNA damage. This evidence concerns the gene NQO1 and hepatocellular carcinoma.